BT Investment Management Ltd acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 311,817 shares of the biopharmaceutical company’s stock, valued at approximately $22,070,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. TD Asset Management Inc. increased its stake in shares of Gilead Sciences by 0.7% during the first quarter. TD Asset Management Inc. now owns 1,007,712 shares of the biopharmaceutical company’s stock worth $68,444,000 after acquiring an additional 7,493 shares during the period. Mizuho Securities USA Inc. acquired a new position in shares of Gilead Sciences during the first quarter worth about $4,928,000. Parkwood LLC increased its stake in shares of Gilead Sciences by 13.2% during the first quarter. Parkwood LLC now owns 114,913 shares of the biopharmaceutical company’s stock worth $7,805,000 after acquiring an additional 13,365 shares during the period. YorkBridge Wealth Partners LLC increased its stake in shares of Gilead Sciences by 6.3% during the first quarter. YorkBridge Wealth Partners LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $229,000 after acquiring an additional 198 shares during the period. Finally, Pax World Management LLC increased its stake in shares of Gilead Sciences by 5.8% during the first quarter. Pax World Management LLC now owns 181,369 shares of the biopharmaceutical company’s stock worth $12,319,000 after acquiring an additional 10,002 shares during the period. Institutional investors own 76.30% of the company’s stock.

A number of research analysts have recently issued reports on GILD shares. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, July 27th. Jefferies Group LLC reissued a “hold” rating and set a $83.00 price objective on shares of Gilead Sciences in a report on Thursday, July 27th. BMO Capital Markets reissued an “outperform” rating and set a $82.00 price objective (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, Deutsche Bank AG reissued a “buy” rating and set a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $84.87.

Gilead Sciences, Inc. (GILD) opened at $72.82 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The stock has a market cap of $95,122.51, a P/E ratio of 7.60, a P/E/G ratio of -1.22 and a beta of 1.13. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the prior year, the business posted $2.75 earnings per share. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. research analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.86%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is 23.69%.

ILLEGAL ACTIVITY WARNING: “BT Investment Management Ltd Takes $22.07 Million Position in Gilead Sciences, Inc. (GILD)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/24/bt-investment-management-ltd-takes-22-07-million-position-in-gilead-sciences-inc-gild.html.

In related news, EVP Gregg H. Alton sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the completion of the transaction, the executive vice president now owns 113,237 shares of the company’s stock, valued at $8,945,723. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold 666,819 shares of company stock valued at $52,303,086 in the last ninety days. 1.30% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.